Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

287
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

180
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration

Pages

  353-359

Abstract

 Objective(s): The Botulism syndrome is caused by types A to G of botulinum neurotoxins. The binding domains of these neurotoxins are immunogenic and considered as appropriate candidate vaccines. Due to the low immunogenicity of recombinant vaccines, there have been many studies on the use of biocompatible carriers such as Chitosan Nanoparticles for the delivery of these vaccines. The aim of this study was evaluating the efficiency of Chitosan Nanoparticles as carriers for a candidate vaccine, binding domain of BoNT/E, through oral and intranasal routes. Materials and Methods: Chitosan Nanoparticles containing rBoNT/E binding domain, were synthesized via ionic gelation. After administration of the Nanoparticles to mice through oral and intranasal routes, antibody titers were assessed by ELISA and, finally, all groups were challenged by active botulinum neurotoxin type E. Results: The groups that received Nanoparticles containing the antigen, through oral and intranasal routes, and the group that received the bare antigen orally, were able to tolerate 5×102 folds of MLD. The intranasally immunized mice by the bare antigen were able to tolerate 2×103 folds of the toxin’ s MLD. Conclusion: It seems that the use of Chitosan Nanoparticles has no significant effect on the protective immunization of the mice against botulinum BoNT/E in either route (P>0. 05), even intranasal administration of the bare antigen gives better mice immunization against the toxin.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Bagheripour, Mohamad Javad, EBRAHIMI, FIROUZ, HAJIZADEH, ABBAS, & NAZARIAN, SHAHRAM. (2019). Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 22(4), 353-359. SID. https://sid.ir/paper/722256/en

    Vancouver: Copy

    Bagheripour Mohamad Javad, EBRAHIMI FIROUZ, HAJIZADEH ABBAS, NAZARIAN SHAHRAM. Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES[Internet]. 2019;22(4):353-359. Available from: https://sid.ir/paper/722256/en

    IEEE: Copy

    Mohamad Javad Bagheripour, FIROUZ EBRAHIMI, ABBAS HAJIZADEH, and SHAHRAM NAZARIAN, “Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration,” IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol. 22, no. 4, pp. 353–359, 2019, [Online]. Available: https://sid.ir/paper/722256/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top